Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors

- Advanced Solid Tumors
- Recruiting

Study Title: A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors

Teva Identifier: TV56278-ONC-10203

ClinicalTrials.gov Identifier: NCT06480552

Study Status: Recruiting

Trial Condition(s): Advanced Solid Tumors

Interventions: Drug: TEV-56278

Study Description: Primary objectives: Characterize the safety and tolerability of TEV-56278 -Determine the Recommended Phase 2 Dose (RP2D). Evaluate antitumor activity of TEV-56278 -Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab. Determine a RP2D of TEV-56278 in combination with pembrolizumab

Print

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult, Older Adult

Age Range: 18 Years to 64 Years

Trial Duration: July 22, 2024 - February 25, 2031

Phase: Phase 1

Study Type

Interventional